Compare IBP & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBP | PRAX |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 9.6B |
| IPO Year | 2014 | 2020 |
| Metric | IBP | PRAX |
|---|---|---|
| Price | $327.74 | $325.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $276.00 | ★ $572.13 |
| AVG Volume (30 Days) | 331.3K | ★ 364.5K |
| Earning Date | 05-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 6.70 | N/A |
| EPS | ★ 9.71 | N/A |
| Revenue | ★ $2,970,800,000.00 | N/A |
| Revenue This Year | $2.46 | N/A |
| Revenue Next Year | $4.53 | $6,395.88 |
| P/E Ratio | $33.67 | ★ N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $150.83 | $26.70 |
| 52 Week High | $349.00 | $354.87 |
| Indicator | IBP | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.55 | 53.52 |
| Support Level | $254.83 | $290.36 |
| Resistance Level | $349.00 | N/A |
| Average True Range (ATR) | 15.69 | 18.34 |
| MACD | -1.41 | -2.56 |
| Stochastic Oscillator | 60.34 | 57.24 |
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.